Shots:
- The US FDA has accepted the BLA and granted the PR with an anticipated PDUFA date as Jul 17, 2021
- The BLA filing marks the milestone on the path to commercialization of narsoplimab
- Narsoplimab is an investigational mAb targeting MASP-2 has received the US FDA’s BTD and ODD to the FDA for each of HSCT-TMA and IgA nephropathy
Click here to read full press release/ article | Ref: Businesswire | Image: Omeros
The post Omeros Reports the US FDA’s Acceptance and Priority Review of BLA for Narsoplimab (OMS721) to Treat HSCT-TMA first appeared on PharmaShots.